15.25

1.46% +0.22

Kyverna Therapeutics Inc (KYTX)

Overview News Price History Discussions Forecast

Kyverna Therapeutics Inc stock is currently priced at $15.25, with a 24-hour trading volume of 459.65K. It has seen a +1.46% increased in the last 24 hours and a -30.43% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $15.48 pivot point. If it approaches the $14.41 support level, significant changes may occur.

Previous Close:

$15.03

Open:

$14.86

24h Volume:

459.65K

Market Cap:

$657.51M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-1.42%

1M Performance:

-30.43%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1D Range:

$14.81

$16.44

52W Range:

$13.96

$30.60

Kyverna Therapeutics Inc Stock (KYTX) Company Profile

Name

Kyverna Therapeutics Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

Address

Employee

Twitter

Next Earnings Date

Latest SEC Filings

KYTX's Discussions on Twitter

Kyverna Therapeutics Inc Stock (KYTX) Latest News

Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?

The Motley Fool

Kyverna Therapeutics Inc Stock (KYTX) Financials Data

There is no financial data for Kyverna Therapeutics Inc (KYTX). Check out other stocks for more information.

Kyverna Therapeutics Inc Stock (KYTX) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Northpond Ventures III GP, LLC	Former 10% Owner	Feb 12 '24	Buy	22.00	450,000	9,900,000	450,000
Bain Capital Life Sciences Inv	10% Owner	Feb 12 '24	Buy	22.00	450,000	9,900,000	3,163,868
Vida Ventures, LLC	10% Owner	Feb 12 '24	Buy	22.00	253,136	5,568,992	252,553

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.